Insulin Aspart Safety Profile & Adverse Events

Safety Profile Overview

Rapid-acting insulin analog for diabetes. Fiasp formulation provides faster onset of action. Monitored for hypoglycemia and injection site reactions.

Generic Name

insulin aspart

Brand Names

NovoLog, Fiasp

Therapeutic Class

Rapid-Acting Insulin

Manufacturer

Novo Nordisk

What Pharma Signal Tracks for Insulin Aspart

Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Insulin Aspart, including serious outcomes, hospitalizations, and deaths.
FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Insulin Aspart products.
Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Insulin Aspart Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Insulin Aspart.

curl "https://api.pharma-signal.com/drug/safety/insulin-aspart" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Try the API API Reference

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Insulin Aspart against other Rapid-Acting Insulin drugs, or explore the full manufacturer portfolio for Novo Nordisk.

Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
Therapeutic class benchmarking — See how Insulin Aspart ranks within Rapid-Acting Insulin on serious event rates.
Company portfolio risk — View all drugs from Novo Nordisk with aggregate risk exposure.
AI analyst briefs — Get a natural-language safety assessment combining all data sources.